Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Ionizing radiation emitter
>>
Phase 2
Welcome,
Profile
Billing
Logout
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
2
4
6
8
10
12
14
16
18
20
LymphoCide Y-90
(epratuzumab Y-90) / Gilead
iopofosine I-131
(CLR 131) / Cellectar
Proxcelan Cesium-131
(cesium-131) / Perspective Therap
SOMther
(lutetium-177 DOTA satoreotide) / Ariceum Therap
AAA603
/ Novartis
Betalutin
(177Lu-satetraxetan-lilotomab) / Nordic Nanovector
177Lu-DOTA-girentuximab
(TLX250) / Telix
177Lu-rhPSMA-10.1
/ Bracco
RNL (rhenium
(186Re) obisbemeda) / Plus Therap
Sartate
(67Cu MeCOSar octreotate) / Clarity Pharma
177Lu-DTPA-omburtamab
/ Y-mAbs Therap
90Y-besilesomab
(TLX66) / Telix
CAM-H2
/ Precirix
LNTH-1095
/ Lantheus
Radspherin
/ Oncoinvent
Tozaride (Rhenium
(Re) 188 P2045) / Andarix
177Lu HTK03170
/ BC Cancer Agency
177Lu-PSMA-R2
/ Novartis
90Y-besilesomab
(TLX66) / Telix
AAA614
/ 3B Pharma, Novartis
Debio 0228
/ Debiopharm, 3B Pharma
Lutetium-177-PEG-αvβ3-IAC
/ Advanced Innovative Partners
sodium iodide I 131
/ Generic mfg.
